149 research outputs found
20 Jaar Interuniversitair Centrum voor Onderwijsonderzoek: een retrospectief
Het Interuniversitair Centrum voor Onderwijsonderzoek (ICO) bestaat meer dan 20 jaar. Dit artikel blikt terug op de ontwikkeling van de school en onderzoekt of de doelstellingen bereikt zijn: (1) het bevorderen van de kwaliteit van het wetenschappelijk onderwijs voor promovendi; (2) het bevorderen van de kwaliteit van het onderwijskundige onderzoek, en (3) het bevorderen van samenwerking. Vervolgens wordt de groei en bloei van ICO besproken aan de hand van een onderzoek, waarbij voor elk van de drie doelen is nagegaan hoe ICO zich over een periode van twee decennia ontwikkeld heeft. Ook wordt stilgestaan bij de korte periode (2004-2005) dat ICO niet erkend werd door de KNAW. De terugblik eindigt met de bespreking van toekomstgerichte ontwikkelingen binnen ICO. De belangrijkste conclusie is dat ICO zijn doelen bereikt heeft. In de toekomst zal internationale samenwerking belangrijker worden en het accent minder op kwaliteitsbewaking van onderzoek en meer op het verzorgen van hoogwaardig onderwijs voor promovendi komen te liggen
Author Correction: A consensus-based transparency checklist.
An amendment to this paper has been published and can be accessed via a link at the top of the paper
A consensus-based transparency checklist
We present a consensus-based checklist to improve and document the transparency of research reports in social and behavioural research. An accompanying online application allows users to complete the form and generate a report that they can submit with their manuscript or post to a public repository
Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre double-blind placebo-controlled clinical trial in the Netherlands
Introduction Delirium in critically ill adults is associated
with prolonged hospital stay, increased mortality and
greater cognitive and functional decline. Current practice
guideline recommendations advocate the use of nonpharmacological strategies to reduce delirium. The
routine use of scheduled haloperidol to treat delirium is
not recommended given a lack of evidence regarding its
ability to resolve delirium nor improve relevant short-term
and longer-term outcomes. This study aims to evaluate
the efficacy and safety of haloperidol for the treatment of
delirium in adult critically ill patients to reduce days spent
with coma or delirium.
Methods and analysis EuRIDICE is a prospective, multicentre, randomised, double-blind, placebo-controlled
trial. Study population consists of adult intensive care
unit (ICU) patients without acute neurological injury who
have delirium based on a positive Intensive Care Delirium
Screening Checklist (ICDSC) or Confusion Assessment
Method for the ICU (CAM-ICU) assessment. Intervention
is intravenous haloperidol 2.5mg (or matching placebo)
every 8 hours, titrated daily based on ICDSC or CAMICU positivity to a maximum of 5mg every 8 hours,
until delirium resolution or ICU discharge. Main study
endpoint is delirium and coma-free days (DCFD) up
to 14 days after randomisation. Secondary endpoints
include (1) 28-day and 1-year mortality, (2) cognitive and
functional performance at 3 and 12 months, (3) patient
and family delirium and ICU experience, (4) psychological
sequelae during and after ICU stay, (4) safety concerns
associated with haloperidol use and (5) cost-effectiveness.
Differences in DCFDs between haloperidol and placebo
group will be analysed using Poisson regression analysis.
Study recruitment started in February 2018 and continues.
Ethics and dissemination The study has been approved
by the Medical Ethics Committee of the Erasmus University
Medical Centre Rotterdam (MEC2017-511) and by the
Institutional Review Boards of the participating sites. Its
results will be disseminated via peer-reviewed publication
and conference presentations
- …